|
Method | Strain | Combination | Observation | Ref. |
|
Etest and time-kill study | hGISA/MSSA | Daptomycin with vancomycin, gentamicin, rifampin, linezolid, quinupristin/ dalfopristin, ampicilin-sulbactam | Etest: additive effect with daptomycin + vancomycin and daptomycin + gentamycin, other combinations with daptomycin indifferent Time-kill study: additive effect with daptomycin + gentamycin, other combinations with daptomycin indifferent | [40] |
|
Etest and time-kill study | GISA/MRSA | Daptomycin with vancomycin, gentamicin, rifampin, linezolid, quinopristine/ dalfopristine, ampicilin-sulbactam | Etest: additive effect only with daptomycin + gentamycin, other combinations with daptomycin indifferent Time-kill study: indifference | [40] |
|
Time-kill study | MRSA | Daptomycin + gentamicin | Synergy in all three strains | [41] |
|
Time-kill study | MRSA | Daptomycin + rifampin | Antagonism in one strain and indifference in two other strains | [41] |
|
Time-kill study | MRSA | Daptomycin at 0.0625 MIC to 2 MIC + oxacillin or ampicillin- sulbactam | Synergy of daptomycin at 0.5 MIC + oxacillin 32 mg/L or ampicillin-sulbactam 2–8 mg/L (ampicillin) | [57] |
|
In vitro model of biofilm | MSSA | Daptomycin 10 mg/kg/d + clarithromycin 250 mg q12 h | Sustained bactericidal activity against planctonic and biofilm bacteria | [54] |
|
In vitro model of biofilm | MRSA | Daptomycin 10 mg/kg/d + rifampin at 600 mg q24 h | Sustained bactericidal activity against planctonic and biofilm bacteria | [54] |
|
In vitro selection for resistance | MRSA and GISA | Daptomycin + 0.25 MIC ampicillin, amoxicillin-clavulanic acid, gentamicin, rifampin | Combination with ampicillin, amoxicillin-clavulanic acid delayed/prevented occurrence of non-susceptibility; rifampin delayed non-susceptibility | [58] |
|
Checkerboard method | MRSA, MSSA | Daptomycin + rifampicin, moxifloxacin or fusidic acid | Daptomycin + fusidic acid: antagonism in one MSSA strain reported | [68] |
|